1 / 27

THE AUSTRALIAN NATIONAL UNIVERSITY

THE AUSTRALIAN NATIONAL UNIVERSITY. Alzheimer’s Disease Christian Stricker ANUMS/JCSMR - ANU Christian.Stricker@anu.edu.au http:/ /stricker.jcsmr .anu.edu. au/Alzheimer.pptx. Aims. The students should know why AD is a neurodegenerative disease;

yanni
Download Presentation

THE AUSTRALIAN NATIONAL UNIVERSITY

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. THE AUSTRALIAN NATIONAL UNIVERSITY Alzheimer’s DiseaseChristian StrickerANUMS/JCSMR - ANUChristian.Stricker@anu.edu.auhttp://stricker.jcsmr.anu.edu.au/Alzheimer.pptx

  2. Aims The students should • know why AD is a neurodegenerative disease; • be aware of what makes up plaques & tangles; • obtain a cell-biological understanding of recent research findings and topics into AD; • appreciate why Aβ and presenilins have multiple actions, both physio- and pathologically; and • understand why AD is largely a synaptic disease.

  3. Contents • Historical note: plaques & tangles • Production of plaques as Aβ oligomers • Tangles and axonal transport • Theory of Aβ cascade and proteolysis • Role of APP • Role of presenilins • Synaptic disease • Reduction in synaptic efficacy • Spine loss and NMDA receptors

  4. History • 25. 11. 1901: Alfred Alzheimer meets Auguste Deter, 51 yo, in Frankfurt. • 8. 4. 1906: Auguste D. dies. • 1906f: Alzheimer publishes first description of this illness with pathological findings (see later). • 1910: Term “Alzheimer’s disease” coined by Kräpelin (German psychiatrist). • “Forgetting”.

  5. Plaques and Tangles Sisodia & St.George-Hyslop (2004), Nat. Rev. Neurosci. 3: 281-290 • Plaque: β-amyloid (Aβ) in centre and dystrophic nerve terminals filled with hyperphosphorylated tau around it. • Tangle: hyperphosphorylated microtubule-associated protein tau assembled into paired helical filaments.

  6. Biochemistry of Plaques • Not only in nerve tissue, but also around blood vessels. • Consist of extracellular protein. • β-amyloid (~40 AA; Aβ) in “precipitated” form. • Assembly of Aβ oligomers. • Proteolyticproduct from amy-loid precursor protein (APP). • High content of heavy metals (Al2+, Zn2+, Cu2+; role?). • Related to amyloid in pancreas in diabetes-2 (adult onset). Van Dorpe et al. (2004), Am. J. Pathol. 157: 1283-1298

  7. Emergence of Plaques • How long does it take to form a plaque? • Tracked in triple-TG mice using in vivo 2-photon microscopy. • Can emerge within a few days; followed by • microglia activation & recruitment (1 – 2 d); • progressive neuritic changes, leading to increasingly dysmor-phicneurites (d–w). Meyer-Luehmann et al. (2008), Nature 451: 720-724

  8. Biochemistry of Tangles http://www.hia.nih.gov • Tau protein stabilizes neurofilaments via cross-linking subunits. • If hyperphosphorylated, tau assembles into tangles (intracellular). • As a consequence, neurofilaments destabilise and break up. • Axonal transport of mitochondria to/from synapse breaks: mitochondrial energy and Ca2+ homeostasis crisis at synapse.

  9. Axonal Transport and Mitochondria Miller & Sheetz (2006), J. Cell Biol. 173: 373-381

  10. Genetics versus Environment Cummings (2004), NEJM 352: 862-866 • Genetic link only for ~1% (autosomal dominant – familial AD, i.e. FAD). • Rest (~99%) sporadic (SAD); most likely a very heterogeneous group. • FAD has early onset (< 65 y) sharing 3 genes: APP, PS1, PS2. Mutation of one of these genes alone is sufficient to cause FAD. • SAD risk factors similar to atherosclerotic disease (BP, lipids, etc). • Disease with important genetic components.

  11. Theories of Disease Generation Schon & Area-Gomez (2013), Mol Cell Neurosci55: 26-36 • No theory is proven… chicken & egg problem. • MAM – Mitochondria-associated membrane – lipid raft containing important signalling proteins (PSEN, BACE, etc.). • Production versus clearance problem (?) Extended from de la Torre (2004), Lancet Neurol3: 184-190

  12. β-Amyloid Generation • Extracellular/intravesicularspace: 2 paths - one on right produces toxic Aβ. • also in secretory vesicles • If APP proteolysis done via α-secretase, NO Aβ is produced. • Amyloidogenic proteolysis: β-secretase cleaves head. • γ-secretase cleaves within membrane. Leads to Aβ production (40, 42 AA). • Particularly, Aβ42 is neurotoxic: • Aggregation • Excitotoxicity • Oxidation • Inflammation • Tau hyperphosphorylation Cummings (2004), NEJM 351: 56-67

  13. What Is APP’s Physiological Role? • Ferro-oxidase function like coerulo-plasmin (Fe2+ oxidation to Fe3+) • Loads Fe3+ into transferrin (Fe homeostasis disease ?): export activity. • Free radical generation → oxid. stress. • Inhibited by Zn2+. • Amine oxidase activity: NA, A, DA↑. • All 3 proteolytic parts have role (?). • Head (N-APP): Development. • Axonal pruning via DR6 that activa-tescaspase 6: Apoptotic pathway. • Aβ (pathogenic part) • As monomer, secreted (synaptic activity): maintains synapses (trophic factor?). • As oligomers, forms amyloid sheets in vesicles (storage?). • Tail (AICD) • Calcium homeostasis. • ATP availability (mitochondria). • Transcriptional modulation. Nicholson (2009), Nature 457: 970-971

  14. Properties of Aβ • Produced in ER; stored in vesicles. • Monomers may be neurotrophic. • Aβsecretion controlled by orexin; under circadian control: sleep ↓; awake ↑. • Production modulated by GPR3 (orphan receptor). • Binds to ACh receptor (pathology). • Oligomers are toxic, esp. Aβ42 • Aβ40 by cleavage in ER; Aβ42 in trans-Golgi network. • As peptides, ability to form cross-β-sheets (“amyloid”), which are poorly soluble. http://commons.wikimedia.org

  15. “Players” in Amyloid Hypothesis • γ-secretase (multi-protein) complex consisting of • nicastrin, • presenilins(PS1, PS2), and • Aph-1. • γ-secretase also activatesnotchsignalling pathway (development; price to pay??). • Aβ self-assembles into oligomers, which become poorly soluble. • Over time, Aβ accumula-tion depends on produc-tion and clearance. Roberson & Mucke (2006), Science 314: 781-784

  16. Presenilins and Ca2+ Homeostasis • Catalyse (as part of γ-se-cretase) formation of Aβ. • Central role in Ca2+ homeostasis (~ 100 nM): • modulate (in SER membr.) • SERCA pump • IP3 receptor • Ryanodine receptor • interact with Ca2+ binding proteins: calpain, etc. • form Ca2+ channels (in expression system): SER Ca2+ leak channel. • are essential for regulating transmitter release (presynaptic Ca2+ stores). • Ca2+ store release activates β-secretase. Green & LaFerla (2009), Neuron 59: 190-194

  17. Functional Studies What is Affected? What are the Consequences?

  18. AD - A Synaptic Disease • Several transgenic mouse models (overexpression). • Human APP mutation transgenic mouse (overexpression). • Early onset in hippocampus (2-10 mo.). • Number of synapses↓. • Number of cells↓. Hsia et al. (1999), PNAS 96: 3228-3233

  19. Changes in Synaptic Efficacy • AMPA-type fEPSPs reduced. • NMDA-dependent LTP does not seem to be affected (other reports differ…). • Larger NMDA receptor currents in transgenic animals. • Potential source of excitotoxicity via Ca2+ “overload”. Hsia et al. (1999), PNAS 96: 3228-3233

  20. “Neurotoxicity” • Organotypic slice cultures of CA1 hippocampus. • Spines are sites of excitatory synapses. • When exposed to control and Aβ42 monomers, spine density is normal. • When exposed to Aβ42oligomers, spine density drops. Shankar et al. (2007), J. Neurosci. 27: 2866-2875

  21. Aβ Secretion Is Activity Dependent • Acutely transfected organotypic hippocam-pal slice cultures (virus). • Neuronal activity secretes Aβ: • TTX blocks APs. • High Mg2+“blocks” transmission. • Picrotoxin (PTX) blocks GABAA receptors (disinhibition). • Flunitrazepam is a GABAA receptor modulator. Kamenetz et al. (2007), Neuron 37: 925-937

  22. Link to Prion-Protein (PrPc) • Neurodegenerative diseases show similar histology. • Aβ42 released at synapses. • Genome-wide screen for Aβoligomers reveals PrPc. • Postsynaptic PrPc lipid rafts. • Functional studies • LTP↓ in wild-type mice. • LTP normal in PrPc KO mice. • α-secretase cleaves PrPc. • Tau, too, complexes with PrPc (postsynaptic toxicity of Aβ – as a Trojan invader?). • PrPc may be good drug target • KO mice viable and LTP normal. Cisse & Mucke (2009), Nature 457: 1090-1091

  23. How is all this in vivo? Still a lot of work to do…

  24. Take-Home Messages • Few cases with genetic background. • More theories than understanding (MAM “disease”). • Plaques are made out of Aβ-oligomers. • Tangles contain of hyperphosphorylated tau. • AD is largely a synaptic disease: • Fewer cells and synapses. • Synapses with smaller efficacy. • Larger contribution of NMDA receptor currents. • NMDA receptor-dependent spine loss. • Activity dependent Aβ secretion.

  25. References • Textbooks • Kandel (4th ed.): 1149 - 1161 • Reviews • Cummings JL (2004) Alzheimer's Disease. N Engl J Med 351: 56-67. • Roberson ED, Mucke L (2006) 100 Years and Counting: Prospects for Defeating Alzheimer's Disease. Science 314: 781-784. • Goedert M, Spillantini MG (2006) A Century of Alzheimer's Disease. Science 314: 777-781. • Selkoe DJ (2002) Alzheimer's Disease Is a Synaptic Failure. Science 298: 789-791. • Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's Disease. Lancet 368: 387-403. • de la Torre JC (2004) Is Alzheimer's Disease a Neurodegenerative or a Vascular Disorder? Data, Dogma, and Dialectics. Lancet Neurol 3: 184-190.

  26. That’s it folks…

More Related